Division of Cardiology, Hallym University Sacred Heart Hospital, Anyang, Korea.
Division of Cardiology, Hallym University Dongtan Sacred Heart Hospital, Hwaseong, Korea.
Korean J Intern Med. 2019 Jan;34(1):11-43. doi: 10.3904/kjim.2018.428. Epub 2018 Dec 28.
Heart failure (HF) is an important cardiovascular disease because of its increasing prevalence, significant morbidity, high mortality, and rapidly expanding health care cost. The number of HF patients is increasing worldwide, and Korea is no exception. There have been marked advances in definition, diagnostic modalities, and treatment of HF over the past four decades. There is continuing effort to improve risk stratification of HF using biomarkers, imaging and genetic testing. Newly developed medications and devices for HF have been widely adopted in clinical practice. Furthermore, definitive treatment for end-stage heart failure including left ventricular assist device and heart transplantation are rapidly evolving as well. This review summarizes the current state-of-the-art management for HF and the emerging diagnostic and therapeutic modalities to improve the outcome of HF patients.
心力衰竭(HF)是一种重要的心血管疾病,因为其患病率不断增加、发病率高、死亡率高和医疗保健费用迅速增加。全球心力衰竭患者的数量正在增加,韩国也不例外。在过去的四十年中,心力衰竭的定义、诊断方法和治疗方法都取得了显著的进展。人们一直在努力使用生物标志物、影像学和基因检测来改善心力衰竭的风险分层。新开发的心力衰竭药物和设备已在临床实践中广泛应用。此外,作为终末期心力衰竭的明确治疗方法,包括左心室辅助装置和心脏移植,也在迅速发展。本综述总结了心力衰竭的最新治疗方法以及新兴的诊断和治疗方法,以改善心力衰竭患者的预后。